Psoriatic arthritis management update - biotherapeutic options.

Saber, Tajvur P; Veale, Douglas J

Authors

Affiliation

Centre for Arthritis Research and Education, Dublin Academic Health Care, St., Vincent's University Hospital, Elm Park, Dublin 4, Ireland.

Issue Date

2012-02-01T10:30:11Z

MeSH

Arthritis, Psoriatic/*drug therapy
Biological Factors/*therapeutic use
Clinical Trials as Topic
Humans
Tumor Necrosis Factor-alpha/*antagonists & inhibitors

Metadata

Show full item record

Citation

J Rheumatol Suppl. 2009 Aug;83:65-8.

Journal

The Journal of rheumatology. Supplement

URI

http://hdl.handle.net/10147/207521

DOI

10.3899/jrheum.090229

PubMed ID

19661546

Abstract

Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy (SpA) occurring in up to 30% of patients with psoriasis. It has a wide variation of annual incidence (median 6.4, range 0.1-3.1 per 10(5) people), based on analysis of 13 incidence and prevalence reviews published between 1987 and December 2006. Conventional treatments with antiinflammatory and disease modifying or antirheumatic drugs are not efficacious in all patients, in particular those with axial disease. This review examines new pharmacological developments in the treatment of PsA with a focus on biologic therapies.

Language

eng

ISSN

0380-0903 (Print)
0380-0903 (Linking)

Collections

St. Vincent's University Hospital